Ipamorelin vs Sermorelin
Ipamorelin is a selective ghrelin-receptor agonist (GHS class). Sermorelin is a GHRH (1-29) analog and the oldest research-grade GHRH tool. They act on different receptors in the GH axis — Ipamorelin triggers a new pulse, Sermorelin extends the natural GHRH-driven pulse. Stacking them is more common than comparing them.
Different tools for different research. Ipamorelin is a ghrelin-pathway GHS — it triggers a GH pulse. Sermorelin is a first-generation GHRH analog — it amplifies an existing pulse. Practitioners rarely pick between them because they pair them (GHS + GHRH). For standalone use, Sermorelin is the cleaner GHRH-only research tool, Ipamorelin is the cleaner GHS-only tool.
Contender A
Ipamorelin
Also: Ipam
Selective GHS-R (ghrelin receptor) agonist — triggers GH pulse from pituitary without touching cortisol or prolactin.
- Half-life
- ~2 hours
- Primary use
- GH pulse trigger research
- Dose range
- 100-300 mcg per dose, 1-3x daily
- Cost tier
- $ · Low sourcing cost
Contender B
Sermorelin
GHRH (1-29) analog — binds hypothalamic GHRH receptor, amplifies natural GH-release rhythm without forcing a new pulse.
- Half-life
- ~10-15 min
- Primary use
- GH pulse amplification research
- Dose range
- 100-300 mcg per dose, pre-bed
- Cost tier
- $ · Low sourcing cost
Detailed Comparison
10 attributes side-by-side. Highlighted rows show where one tool has a clear structural edge.
| Attribute | Ipam | Sermorelin | Edge |
|---|---|---|---|
Receptor class | GHS (ghrelin) | GHRH | Tie |
Mechanism type | Triggers pulse | Amplifies pulse | Tie |
Half-life | ~2 hours | ~10-15 min | Ipam |
Evidence maturity | Expert / experimental | FDA-approved history (withdrawn commercially) | B |
Selectivity for GH axis | Very high | Very high | Tie |
Appetite effect | Mild increase | Neutral | B |
Effective alone | Modest | Modest | Tie |
Stacks with the other | Yes, synergistic | Yes, synergistic | Tie |
Dosing cadence | 1-3x daily | Pre-bed standard | Ipam |
Pituitary exhaustion risk | Low | Low | Tie |
Practitioner Notes
Sourced from practitioner-validated protocols — not PubMed abstracts.
The right framing: these are not competitors, they're the two sides of the GH axis. Ipamorelin is the GHS half (ghrelin pathway); Sermorelin is the GHRH half (hypothalamic pathway). The reason CJC-1295 mostly replaced Sermorelin in practitioner protocols is half-life — CJC-1295 without DAC runs ~30 min vs Sermorelin's ~10-15 min, which gives a longer window for the pituitary to respond before the GHRH signal clears.
Sermorelin still has a place. It has decades of clinical use behind it (once FDA-approved), and the receptor-binding profile is more native to endogenous GHRH than CJC-1295's modified analog. Research protocols interested in matching the natural GHRH signal as closely as possible sometimes prefer Sermorelin for that reason.
In the practitioner corpus, standalone Sermorelin protocols are rare. Standalone Ipamorelin protocols exist but are usually designed for appetite-augmentation research rather than GH-pulse optimization. The default stack is Ipamorelin + CJC-1295 without DAC; Sermorelin shows up as a substitute for CJC-1295 when the research explicitly wants the native GHRH profile.
Stacking & Switching
Can these be combined? Should you switch from one to the other? Titration considerations.
Stack compatibility: See the “Stacks well” or “Stack compatibility” row in the comparison table above. When the edge column shows Tie, both compounds run together cleanly. When one compound dominates, check the protocol notes for the specific stacking pattern practitioners use.
Switching protocol: The general pattern across practitioner protocols: hold the current dose stable, introduce the new compound at its lowest titration step, run both for a 1-2 week cross-over window, then taper the original. Abrupt switches produce rebound effects as the original compound's steady state clears.
Half-life math: DoseCraft's PK-aware AI models half-life decay and stack overlap across every pairing above. The 20x20 interaction matrix flags contraindications automatically — no manual math, no overlapping-signal blindspots.
Frequently Asked Questions
Indexed for SERP FAQPage rich results.
Is Ipamorelin better than Sermorelin?
+
They do different things — Ipamorelin triggers a GH pulse, Sermorelin amplifies an existing pulse. 'Better' depends on the research question. In practice, practitioners stack them or use CJC-1295 as a more practical GHRH analog.
Why did Sermorelin get replaced by CJC-1295 in most stacks?
+
Half-life. Sermorelin clears in ~10-15 min, which gives the pituitary a narrow response window. CJC-1295 without DAC runs ~30 min — longer window, larger integrated signal, same selectivity.
Does Sermorelin still have a use?
+
Yes — research protocols explicitly designed to mimic the endogenous GHRH signal use Sermorelin because it's structurally closest to native GHRH (1-29). It's also the tool with the longest historical safety record in the class.
Can I run Sermorelin solo?
+
You can, but the corpus suggests pairing with Ipamorelin multiplies the GH-pulse response. Standalone Sermorelin protocols produce real but smaller GH elevation.
What about CJC-1295 vs Sermorelin directly?
+
Both are GHRH analogs. CJC-1295 has longer half-life and is more practical for most protocols; Sermorelin is structurally closer to native GHRH and has longer historical use. See our Ipamorelin vs CJC-1295 comparison for the default stack.
Related Comparisons
GH Axis
Ipamorelin vs CJC-1295
Ipamorelin mimics ghrelin and triggers a GH pulse via the growth hormone secretagogue receptor. CJC-1295 is a GHRH analog that extends and amplifies the natural GH pulse window. They hit different receptors and produce a bigger, cleaner GH pulse when stacked than either does alone.
ReadGH Axis
CJC-1295 with DAC vs without DAC
CJC-1295 without DAC (also called Mod GRF 1-29) has a ~30-minute half-life and preserves the natural pulsatile GH rhythm. CJC-1295 with DAC attaches a Drug Affinity Complex that extends the half-life to ~8 days, producing a flat elevated GH baseline instead of pulses. The choice is pulsatility vs steady-state — and pulsatility is what you usually want.
ReadHealing
BPC-157 vs TB-500
BPC-157 is a pentadecapeptide derived from gastric juice with strong localized healing signals, especially in GI and tendon research. TB-500 is a fragment of Thymosin Beta-4 with systemic actin-binding activity driving cell migration, angiogenesis, and broad tissue recovery. Half-lives and delivery profiles are very different; so are their niches.
ReadTrack Your Protocol with PK-Aware AI
Compound choice is step one. DoseCraft models half-life decay, stack overlap, and titration paths across 90+ peptides — a pharmacokinetic reasoning layer on top of practitioner-validated protocols.
Track your protocol with PK-aware AI in DoseCraftResearch-only disclaimer: This comparison is for research and educational purposes only. Peptides referenced are sold for research use by third-party suppliers. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a licensed physician before acting on any peptide protocol information.